Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ECOG-E3503T1 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment with erlotinib.
PURPOSE: This laboratory study is developing a model to predict progression-free survival after erlotinib in patients with non-small cell lung cancer.
OBJECTIVES:
OUTLINE: Tissue samples are analyzed by whole genome mapping for single nucleotide polymorphism (SNP) rate and by signal detection rate and by quantitative immunohistochemistry for mesenchymal (vimentin/cytokeratin) and epithelial (E-cadherin) marker transitions. After biomarker identification and gene mapping are complete, a model to predict progression-free survival in these patients is developed.
PROJECTED ACCRUAL: A total of 137 samples will be accrued for this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| gene mapping | Genetic | |||
| polymorphism analysis | Genetic | |||
| diagnostic laboratory biomarker analysis | Other | |||
| immunohistochemistry staining method | Other |
| Measure | Description | Time Frame |
|---|---|---|
| Mesenchymal and epithelial markers | Mesenchymal and epithelial markers | 1 month |
| Loss of epithelial markers (E-cadherin) and gain of mesenchymal markers (vimentin/cytokeratin co-expression) | Loss of epithelial markers (E-cadherin) and gain of mesenchymal markers | 1 month |
| Correlation of progression-free survival (PFS) by mesenchymal and epithelial markers | Correlation of progression-free survival (PFS) by mesenchymal and epithelial markers | 1 month |
| Identification of a single nucleotide polymorphism profile via whole genome mapping and other known biomarkers to predict PFS | Identification of a single nucleotide polymorphism profile via whole genome mapping and other known biomarkers to predict PFS | 1 month |
Not provided
Not provided
DISEASE CHARACTERISTICS:
Diagnosis of non-small cell lung cancer, including any of the following subtypes:
Stage IIIB or IV or recurrent disease
Must have received treatment with erlotinib hydrochloride on clinical trial ECOG-E3503
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
Samples submitted for research from patients participating in E3503
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jill Kolesar, PharmD | University of Wisconsin, Madison | Study Chair |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20035238 | Result | Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. 2010 Feb;5(2):169-78. doi: 10.1097/JTO.0b013e3181c8cbd9. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D000077192 | Adenocarcinoma of Lung |
| D002282 | Adenocarcinoma, Bronchiolo-Alveolar |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D002874 | Chromosome Mapping |
| D054458 | Amplified Fragment Length Polymorphism Analysis |
| D007150 | Immunohistochemistry |
| ID | Term |
|---|---|
| D005821 | Genetic Techniques |
| D008919 | Investigative Techniques |
| D016172 | DNA Fingerprinting |
| D016133 | Polymerase Chain Reaction |
| D021141 | Nucleic Acid Amplification Techniques |
| D006651 | Histocytochemistry |
| D003584 | Cytological Techniques |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D006652 | Histological Techniques |
| D007158 | Immunologic Techniques |
Not provided
Not provided